These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32326537)

  • 1. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.
    Santoro M; Moccia M; Federico G; Carlomagno F
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32326537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
    Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
    Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RET oncogene in papillary thyroid carcinoma.
    Prescott JD; Zeiger MA
    Cancer; 2015 Jul; 121(13):2137-46. PubMed ID: 25731779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.
    Staubitz JI; Musholt TJ; Schad A; Springer E; Lang H; Rajalingam K; Roth W; Hartmann N
    Cancer Genet; 2019 Oct; 238():10-17. PubMed ID: 31425920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer.
    Chen M; Xue J; Sang Y; Jiang W; He W; Hong S; Lv W; Xiao H; Liu R
    BMC Cancer; 2023 Apr; 23(1):363. PubMed ID: 37081420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
    Khan MS; Qadri Q; Makhdoomi MJ; Wani MA; Malik AA; Niyaz M; Masoodi SR; Andrabi KI; Ahmad R; Mudassar S
    Pathol Oncol Res; 2020 Jan; 26(1):507-513. PubMed ID: 30467698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
    Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET fusion as a novel driver of medullary thyroid carcinoma.
    Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
    J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.
    Lehman CE; Dillon LW; Nikiforov YE; Wang YH
    Carcinogenesis; 2017 Mar; 38(3):293-301. PubMed ID: 28069693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.
    Santoro M; Dathan NA; Berlingieri MT; Bongarzone I; Paulin C; Grieco M; Pierotti MA; Vecchio G; Fusco A
    Oncogene; 1994 Feb; 9(2):509-16. PubMed ID: 8290261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of RET/PTC1 and RET/PTC3 oncoproteins in radiation-induced papillary thyroid carcinomas on amounts of cytoskeletal protein species.
    Zeindl-Eberhart E; Liebmann S; Jungblut PR; Mattow J; Schmid M; Kerler R; Rabes HM
    Amino Acids; 2011 Jul; 41(2):415-25. PubMed ID: 20839015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.